6937-15-1Relevant articles and documents
Method of preparing linezolid
-
Paragraph 0048; 0049; 0050, (2018/04/02)
The invention relates to a method of preparing an oxazolidine antibacterial agent-linezolid. The method includes: enabling (S, E)-N-benzal-1-(ethylene oxide-2-group)-methylamine and morpholino fluoro-phenyl carbamate to react in a non-nucleophilic agent under action of alkali and catalyst to obtain a high-purity imine intermediate; subjecting the intermediate to hydrolysis and acylation to generate linezolid. The method is high in yield, simple to operate, mild in reaction condition and suitable for industrial production.
OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS
-
Page/Page column 46, (2017/05/19)
The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosiscomprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or apharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
Method for preparing 3-hydroxyazetidine hydrochloride and tert-butyl 3-hydroxyazetidine-1-carboxylate
-
Paragraph 0048; 0049; 0050, (2017/08/30)
The invention discloses a method for preparing 3-hydroxyazetidine hydrochloride and tert-butyl 3-hydroxyazetidine-1-carboxylate and relates to the field of drug synthesis. The method comprises the following steps: taking 3-sustituted-1,2-epoxypropane, a benzaldehyde compound and ammonium hydroxide as initiators so as to obtain a first intermediate with an imine structure; and hydrolyzing the first intermediate so as to obtain hydroxylammonium salt, and performing ring closing, thereby obtaining the target product. On the basis of the preparation method, two different synthetic strategies of sequentially performing ring closing and introducing a Boc group and sequentially introducing the Boc group and performing ring closing are respectively adopted from the hydroxylammonium salt, and then tert-butyl 3-hydroxyazetidine-1-carboxylate is prepared at high efficiency. According to the previous three preparation methods, the harsh conditions that a Pd/C catalyst and hydrogen are used and the like are avoided, and extra process steps are avoided. The whole process flow is reasonable in design, and the method is mild in conditions, simple and convenient to operate, readily available in raw materials, high in production efficiency and very suitable for large-scale industrial production.
A Process for preparing linezolid and its intermediate
-
Paragraph 0075-0080, (2018/02/14)
The present invention relates to a manufacturing method of linezolid which is an oxazolidinone-based antibiotic. More specifically, the present invention relates to a novel manufacturing method of linezolid; and to an intermediate compound of linezolid, and the manufacturing method of linezolid uses a novel halomethyl ethanone compound as an intermediate for the manufacture of linezolid, thereby simplifying a manufacturing process and reducing manufacturing costs in comparison with a conventional manufacturing method. The intermediate compound is a novel compound, and is an (S)-1-(5-(halomethyl)-2, 2-dimethyl oxazolidine-3-yl)ethanone compound represented by chemical formula 1. In chemical formula 1, R is one element selected from F, Cl, Br, and I. The manufacturing method of linezolid comprises: a step (A) of performing a reaction process of a compound represented by chemical formula 1 and a compound represented by chemical formula 2 to manufacture a compound represented by chemical formula 3; a step (B) of hydrolyzing the compound represented by chemical formula 3 to obtain a compound represented by chemical formula 4; and a step (C) of performing carbonylation of the compound represented by chemical formula 4.COPYRIGHT KIPO 2016
4-Benzoylamino-3-hydroxybutyric acid, historically first "anomalous racemate": Reinvestigation
Bredikhin, Alexander A.,Bredikhina, Zemfira A.,Zakharychev, Dmitry V.,Samigullina, Aida I.,Gubaidullin, Aidar T.
supporting information, p. 1362 - 1373 (2015/05/20)
Chiral 4-benzoylamino-3-hydroxybutyric acid (1) was recognized in 1930 as the first example of "anomalous racemates" (correct to say, anomalous conglomerates), that is, specific addition compounds formed by different enantiomers in unequal ratio. Through the comparative (racemic against homochiral samples) inspection of the IR spectra, single crystal X-ray diffraction, PXRD analysis, and solubility data we have found that this substance forms normal racemic compound in the solid state, and must be excluded from the very short list of anomalous conglomerates. At the same time homo-1 is dissolved in 25 times better than rac-1, and this feature belongs to another interesting and rare type, namely, "anticonglomerates". Some of the reasons for this behavior are discussed.
Synthesis and in vitro antibacterial activity of novel fluoroalkyl-substituted pyrazolyl oxazolidinones
Yan, Lili,Wu, Jingjing,Chen, Heng,Zhang, Shaowu,Wang, Zhi,Wang, Hui,Wu, Fanhong
, p. 73660 - 73669 (2015/09/15)
A series of novel oxazolidinone derivatives bearing fluoroalkyl-substituted pyrazole as the C-ring structure were designed, synthesized and evaluated for their antibacterial activity against six Gram-positive bacterial pathogens. Most of the target compounds have good antibacterial activity. Especially, compounds 13f, 13i and 13l show excellent activity comparable to linezolid.
PROCESS FOR OBTAINING RIVAROXABAN AND INTERMEDIATE THEREOF
-
Paragraph 0053, (2014/05/20)
This invention relates to a procedure for obtaining a thiophene-2-carboxamide compound, specifically rivaroxaban, which comprises the (i) fragmentation of the N═C bond of a compound of formula 23 where R1 is selected among hydrogen, halogen, and (C1-C6)alkyl; and (ii) acylation of the resulting intermediate with 5-chloro-tiofen-2-carbonyl chloride in a solvent medium, in the presence of a base. The invention also relates to the compounds of formula 23 and their use in the obtention of rivaroxaban.
PROCESSES FOR PREPARING RIVAROXABAN
-
Page/Page column 20, (2013/10/22)
Processes and intermediates for preparing rivaroxaban, and analogs and derivatives thereof, and pharmaceutically acceptable salts of each of the foregoing, are described herein.
PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL) PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF
-
Page/Page column 52, (2013/04/13)
TThe present invention provides processes for the preparation of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide (I) and intermediates thereof. Also provides novel intermediates and their use in the synthesis of oxazolidine derivatives.
PROCESS FOR OBTAINING RIVAROXABAN AND INTERMEDIATE THEREOF
-
Page/Page column 15, (2012/12/13)
This invention relates to a procedure for obtaining a thiophene-2-carboxamide compound, specifically rivaroxaban, which comprises the (i) fragmentation of the N=C bond of a compound of formula 23 where R1 is selected among hydrogen, halogen, and (C1-C6)alkyl; and (ii) acylation of the resulting intermediate with 5-chloro-tiofen-2-carbonyl chloride in a solvent medium, in the presence of a base. The invention also relates to the compounds of formula 23 and their use in the obtention of rivaroxaban.
